Several reports confirmed their ability to cross the blood–brain barrier and proved their potency in the treatment of Alzheimer’s disease via interfering with some potential targets, such as AChE and/or ERK2 [12,25]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.